Continuous Glucose Monitoring Devices Market, By Component, By Device Type, By Technology, By Usage Mode, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

The Continuous Glucose Monitoring Devices Market size was valued at US$ 5,602.32 Million in 2024, expanding at a CAGR of 7.44% from 2025 to 2032.
The Continuous Glucose Monitoring (CGM) Devices Market consists of wearable or implantable systems that track glucose levels in real time to aid in diabetes management. With diabetes cases projected to reach 853 million globally by 2050, demand for real-time glucose monitoring is rising as patients seek to avoid complications and reduce dependence on fingerstick tests. Adoption is further supported by growing preference for minimally invasive technologies, integration with smartphone apps, and favorable reimbursement in developed nations. However, high device costs, limited insurance coverage in low-income regions, and concerns over data accuracy in early-generation systems remain key restraints. Still, the market offers strong opportunities with increasing use among Type 1 pediatric populations, rising partnerships between medtech and digital health firms, and development of fully non-invasive sensors that may soon reach regulatory approval.
Continuous Glucose Monitoring Devices Market- Market Dynamics

Rising Diabetes Burden and Demand for Real-Time Monitoring Accelerate Growth of the Continuous Glucose Monitoring Devices Market
The rising global burden of diabetes and the need for real-time glucose monitoring are driving widespread adoption of Continuous Glucose Monitoring (CGM) devices. According to the International Diabetes Federation, over 589 million people were living with diabetes in 2024, with that number expected to rise significantly by 2050. CGMs, such as the FreeStyle Libre by Abbott and Dexcom G7, provide continuous glucose tracking without routine finger pricks, improving glycemic control and reducing long-term complications. The U.S. Centers for Medicare & Medicaid Services (CMS) expanded coverage for CGM devices in 2023 to include more Type 2 diabetes patients using insulin, enhancing accessibility. Meanwhile, NHS England is progressively incorporating CGMs into its primary care diabetes programs, signaling broader public health adoption.
Continuous Glucose Monitoring Devices Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.44% over the forecast period (2025-2032)
Based on Component segmentation, Sensors were predicted to show maximum market share in the year 2024
Based on Device Type segmentation, Real-time CGM (rtCGM) was the leading Device Type in 2024
Based on Technology segmentation, Enzyme-based Technology was the leading Technology in 2024
Based on Usage Mode segmentation, Disposable was the leading Usage Mode in 2024
Based on end user segmentation, Home Healthcare Settings was the leading end user in 2024
On the basis of region, North America was the leading revenue generator in 2024
Continuous Glucose Monitoring Devices Market- Segmentation Analysis:

The Global Continuous Glucose Monitoring Devices Market is segmented on the basis of Component, Device Type, Technology, Usage Mode, End User, and Region.
The market is divided into three categories based on Component: Sensors, Transmitters, Receivers, and Integrated Insulin Pumps. Sensors dominate the CGM market as the core component for real-time glucose monitoring. Transmitters follow, enabling data transfer. Receivers rank next for data display, while integrated insulin pumps, though advanced, are adopted primarily by insulin-dependent users due to higher costs.
The market is divided into two categories based on Device Type: Real-time CGM (rtCGM) and Intermittently Scanned CGM (isCGM/Flash). Real-time CGM (rtCGM) leads the market due to continuous data visibility, trend alerts, and superior glycemic control, making it preferred for Type 1 and insulin-dependent Type 2 diabetes patients. Intermittently scanned CGM follows, favored for affordability and ease of use.
Continuous Glucose Monitoring Devices Market- Geographical Insights

North America dominates the CGM market due to strong regulatory support, early adoption of digital health tools, and the presence of key players like Abbott and Dexcom. In the U.S., CMS has expanded coverage to include more patients with Type 2 diabetes, further boosting device accessibility. Europe follows closely, with increasing integration of CGM devices into public health systems. The NHS in the UK has made CGMs available to children and young people with Type 1 diabetes, enhancing early intervention efforts. Asia-Pacific is witnessing rapid adoption, especially in countries like India and China, driven by rising diabetes prevalence and growing awareness of digital glucose monitoring. Abbott’s acquisition of Bigfoot Biomedical and Dexcom’s collaboration with Verily are examples of strategic moves enhancing global outreach and local customization. These efforts indicate a strong global push toward smarter, more accessible diabetes management solutions.
Continuous Glucose Monitoring Devices Market- Competitive Landscape:

The competitive landscape of the CGM devices market is driven by innovation, strategic partnerships, and expansion into new user segments. In September 2023, Abbott completed its acquisition of Bigfoot Biomedical, integrating smart insulin-pen technology with its FreeStyle Libre system to advance automated insulin delivery solutions. Meanwhile, Dexcom has deepened its collaboration with Verily (Google's life sciences division) to co-develop next-gen CGM sensors, with a $250 million revised partnership agreement signed in 2021. Dexcom also launched Stelo, an OTC sensor approved in August 2024, targeting early-stage or non-insulin users. Additionally, Abbott responded by launching its own consumer-focused OTC CGM, Lingo, in September 2024 to broaden access. These moves underscore fierce competition centered on the integration of CGM with insulin delivery systems, consumer-friendly accessibility, and advanced sensor development.

Recent Developments:

In June 2025, Tracky, an Indian startup by DrStore Healthcare Services, launched India’s first Bluetooth-enabled continuous glucose monitor. The device offers automatic syncing every three minutes via a mobile app, delivers real-time glucose alerts, and is positioned as a cost‑effective, user-friendly diabetes management tool.
In September 2024, Senseonics won FDA clearance for Eversense 365, the first-ever one-year implantable continuous glucose monitoring system for adults with type 1 and type 2 diabetes, offering extended sensor longevity, rechargeable transmitter, and integration with automated insulin delivery systems
In August 2024, Abbott entered a global partnership with Medtronic to integrate its FreeStyle Libre CGM technology with Medtronic’s automated insulin delivery and smart insulin pen systems. The collaboration enables automatic insulin adjustments based on real-time glucose data.
In August 2024, Dexcom introduced Stelo, the first FDA-cleared over-the-counter CGM—no prescription needed, designed for adults not using insulin, featuring 15-day wear, real-time tracking via smartphone, and lifestyle-focused insights on diet and activity.
In July 2024, Roche received CE‑mark approval for its Accu‑Chek SmartGuide AI‑enabled continuous glucose monitoring system, offering real-time readings every five minutes, predictive hypoglycemia alerts, and two-hour glucose trend forecasts to enhance diabetes self‑management.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Dexcom
Abbott Laboratories
AgaMatrix
Ascensia Diabetes Care
B. Braun Melsungen AG
Beta Bionics
BioTelemetry (Philips)
Diabeloop
Eversense
Glooko
Insulet Corporation
i-SENS, Inc.
Medtronic
Nemaura Medical
Nova Biomedical
POCTech
Roche Diabetes Care
Senseonics
Tandem Diabetes Care
Ypsomed
Others

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032

Sensors
Transmitters
Receivers
Integrated Insulin Pumps

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY DEVICE TYPE- MARKET ANALYSIS, 2019 - 2032

Real-time CGM (rtCGM)
Intermittently Scanned CGM (isCGM/Flash)

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

Enzyme-based Technology
Optical-based Technology

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY USAGE MODE- MARKET ANALYSIS, 2019 - 2032

Disposable
Reusable

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Home Healthcare Settings
Diabetes Care Centers

GLOBAL CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more